Hemolytic-uremic syndrome and myocardial dysfunction in a 9-month-old boy.
Cardiovascular dysfunction in patients with hemolytic-uremic syndrome (HUS) may be related to secondary issues such as volume overload, hypertension or electrolyte disturbances including hyperkalemia. Additionally, primary myocardial involvement has been increasingly recognized as a potential comorbid feature of HUS. We report a 9-month-old child with HUS who developed clinical signs of poor myocardial function with depressed myocardial function noted by echocardiography. Supportive care including mechanical ventilation and inotropic agents were necessary for approximately 10 days. Follow-up echocardiography revealed return of normal ventricular function. Previous reports of primary cardiac involvement with HUS have included thrombotic microangiopathy of the coronary vasculature resulting in myocardial ischemia, myocardial infarction or depressed myocardial function, myocarditis, congestive heart failure with dilated cardiomyopathy and pericardial effusion with tamponade. Given the potential for morbidity and mortality during the preoperative period in patients with HUS, anesthesiologists involved in the care of such patients should be aware of the potential for myocardial involvement in this disease process. Preoperatively, the routine evaluation of myocardial function may be indicated.
Tobias
Joseph D
JD
Department of Anesthesiology, University of Missouri, Columbia, MO 65212, USA. Tobiasj@health.missouri.edu
D000740:Anemia / Q000150:complications; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D009202:Cardiomyopathies / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D002316:Cardiotonic Agents / Q000008:administration & dosage; D004298:Dopamine / Q000008:administration & dosage; D004562:Electrocardiography / Q000379:methods; D006463:Hemolytic-Uremic Syndrome / Q000150:complications*; D006801:Humans; D007223:Infant; D007442:Intubation, Intratracheal / Q000379:methods; D008297:Male; D000077731:Meropenem; D020105:Milrinone / Q000008:administration & dosage; D045283:Natriuretic Agents / Q000008:administration & dosage; D020097:Natriuretic Peptide, Brain / Q000008:administration & dosage; D009846:Oliguria / Q000150:complications; D010530:Peritoneal Dialysis / Q000379:methods; D006435:Renal Dialysis / Q000379:methods; D051437:Renal Insufficiency / Q000150:complications; D012121:Respiration, Artificial / Q000379:methods; D013845:Thienamycins / Q000008:administration & dosage; D014640:Vancomycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D002316:Cardiotonic Agents; D045283:Natriuretic Agents; D013845:Thienamycins; D020097:Natriuretic Peptide, Brain; D014640:Vancomycin; D000077731:Meropenem; D020105:Milrinone; D004298:Dopamine